Leerink Partnrs Has Positive Outlook of Vericel Q4 Earnings

Vericel Co. (NASDAQ:VCEL - Free Report) - Research analysts at Leerink Partnrs increased their Q4 2025 EPS estimates for Vericel in a note issued to investors on Thursday, May 8th. Leerink Partnrs analyst M. Kratky now anticipates that the biotechnology company will earn $0.48 per share for the quarter, up from their prior forecast of $0.45. The consensus estimate for Vericel's current full-year earnings is $0.14 per share. Leerink Partnrs also issued estimates for Vericel's FY2029 earnings at $2.76 EPS.

Vericel (NASDAQ:VCEL - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.14). The business had revenue of $52.60 million during the quarter, compared to analysts' expectations of $53.86 million. Vericel had a return on equity of 1.48% and a net margin of 1.56%. Vericel's revenue for the quarter was up 2.6% compared to the same quarter last year. During the same quarter last year, the company posted ($0.08) EPS.

VCEL has been the topic of a number of other research reports. Stephens restated an "overweight" rating and issued a $65.00 price objective on shares of Vericel in a report on Wednesday, January 15th. StockNews.com upgraded shares of Vericel from a "sell" rating to a "hold" rating in a report on Saturday, March 8th. Truist Financial cut their price objective on shares of Vericel from $61.00 to $51.00 and set a "buy" rating on the stock in a report on Friday, April 11th. Canaccord Genuity Group increased their price target on shares of Vericel from $64.00 to $67.00 and gave the company a "buy" rating in a report on Monday, February 3rd. Finally, HC Wainwright reiterated a "buy" rating and set a $60.00 price target on shares of Vericel in a report on Friday, February 28th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $60.86.

Vericel Stock Performance

Shares of VCEL opened at $41.73 on Monday. The stock has a market cap of $2.09 billion, a PE ratio of 695.62 and a beta of 1.31. Vericel has a fifty-two week low of $37.39 and a fifty-two week high of $63.00. The firm's 50-day simple moving average is $43.19 and its two-hundred day simple moving average is $51.27.

Institutional Investors Weigh In On Vericel

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. CenterBook Partners LP purchased a new stake in Vericel in the first quarter worth approximately $888,000. Gagnon Securities LLC purchased a new stake in Vericel in the first quarter worth approximately $137,000. Geneva Capital Management LLC boosted its holdings in Vericel by 24.2% in the first quarter. Geneva Capital Management LLC now owns 1,365,744 shares of the biotechnology company's stock worth $60,939,000 after purchasing an additional 265,956 shares during the last quarter. US Bancorp DE boosted its holdings in Vericel by 29.9% in the first quarter. US Bancorp DE now owns 3,071 shares of the biotechnology company's stock worth $137,000 after purchasing an additional 706 shares during the last quarter. Finally, Federated Hermes Inc. boosted its holdings in Vericel by 6.4% in the first quarter. Federated Hermes Inc. now owns 1,193,759 shares of the biotechnology company's stock worth $53,266,000 after purchasing an additional 71,386 shares during the last quarter.

Insider Activity

In other news, CEO Dominick Colangelo sold 24,850 shares of the stock in a transaction that occurred on Thursday, April 10th. The shares were sold at an average price of $41.89, for a total transaction of $1,040,966.50. Following the sale, the chief executive officer now owns 260,354 shares in the company, valued at $10,906,229.06. This represents a 8.71% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 5.20% of the company's stock.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.